ZimVie — Q1 2024 Earnings Presentation
15 slides from ZimVie's earnings presentation, May 8, 2024
Slide 1: A Global Dental Leader
A Global Dental Leader May 2024 Exhibit 99.2
Slide 2: Forward-Looking Statements and Non-GAAP Measures
Forward-Looking Statements and Non-GAAP Measures Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995 This presentation contains forward-looking statements within the meaning of federal securities laws, including, among others, any statements about our expectations, plans
Slide 3: ZimVie: A Global Dental Leader
ZimVie: A Global Dental Leader Powerful, market-leading portfolio of premium implants, restorative implant solutions, biomaterials solutions, and digital dentistry technologies driven by continuous innovation Well positioned to accelerate growth within large, attractive, and underserved markets thro
Slide 4: Driving Adoption Across our Diversified Portfolio of Solutions
Driving Adoption Across our Diversified Portfolio of Solutions Increase Penetration of Implants and Restorations Through Continued Innovation and Commercial Execution Implant Growth: Innovation & Execution Leverage Leadership Position to Drive Implant Conversion Biomaterials Pull-Through Scale ZimVi
Slide 5: Supported by World-Class Education and Training
Supported by World-Class Education and Training Training and Manufacturing Facilities now Co-Located with Global Headquarters in Palm Beach Gardens, FL The “PBG Institute” Dental Training Facility Modern 11,000 Sq. Ft. Facility Cadaver Lab On-Site Mill Fully Integrated Digital Workflow with 3D Print
Slide 6: Dental Implants: Portfolio Overview
Comprehensive premium implant line meets varying needs of oral surgeons and dental clinicians with a wide range of indications Dental Implants: Portfolio Overview Key Products Full range of abutments, copings and analogs Implants, surgical tools, abutments, restorative components TSX™ Implant T3® PR
Slide 7: Biomaterials: Portfolio Overview
Biomaterials: Portfolio Overview Puros® Allograft Bone Block Barrier Membranes Xenograft and synthetic bone grafts RegenerOss® Cortico – Cancellous Particulate RegenerOss® Bone Graft Plug Puros® Allograft Products Biotivity™ A/C Plus Membrane Leading biomaterial solutions increase the size of our pa
Slide 8: Digital Dentistry: Portfolio Overview
Digital Dentistry: Portfolio Overview BellaTek® System GenTek™ System SmileZ Today ® Encode ® System RealGUIDE™ Software RealGuide V5.0 Virtual treatment planning CAD/CAM workflow systems A fully integrated and efficient workflow with predictable outcomes increases adoption Key Products Recent Innov
Slide 9: Committed to Executing Strategic Transformation
Committed to Executing Strategic Transformation Position the business for sustainable growth Address and reduce stranded cost Optimize manufacturing and supply chain capabilities Continue innovating to increase ease of procedures Expand product offerings across geographies Accelerate digital adoptio
Slide 10: Financial Profile and Outlook
Financial Profile and Outlook Net Sales Adjusted EBITDA Q1 2024* FY 2024 Transition year in 2024 to build a strong foundation for long-term performance $118.2M $12.5M(1) $450M-$460M $60M-$65M(2) Total Debt $508.8M Drivers of progress Expanding portfolio adoption within large, underserved dental mark
Slide 11: Experienced Executive Leadership Team
Experienced Executive Leadership Team Vafa Jamali Chief Executive Officer Heather Kidwell SVP, Chief Legal, Compliance, & HR Officer Rich Heppenstall EVP, Chief Financial Officer Ann Vu SVP, Chief Quality and Regulatory Affairs Officer Stephen Rondeau SVP, Chief Information Officer Indraneel Kanagle
Slide 12: Appendix
Dp Appendix < ZimVie
Slide 13: Note on Non-GAAP Financial Measures
Note on Non-GAAP Financial Measures This presentation includes non-GAAP financial measures that differ from financial measures calculated in accordance with U.S. generally accepted accounting principles (“GAAP”). These non-GAAP financial measures may not be comparable to similar measures reported by
Slide 14: Reconciliation of Adjusted EBITDA
Reconciliation of Adjusted EBITDA (in thousands) 1. Current and prior year restructuring activities to better position our organization for future success based on the existing business environments, as well as sale of the spine business in the current year. 2. Acquisition, integration, divestiture
Slide 15: Reconciliation of Adjusted Net (Loss) Income and Adjusted EPS
Reconciliation of Adjusted Net (Loss) Income and Adjusted EPS (in thousands, except per share data) 1. Restructuring activities to better position our organization for future success based on the current business environment and sale of the spine business. 2. Acquisition, integration, divestiture an